{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:17:09Z","timestamp":1783063029616,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36231-9","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:46:15Z","timestamp":1777715175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Chandrani","family":"Khatri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajit","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanta","family":"Patowary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"22","key":"36231_CR1","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.3390\/cancers14225580","volume":"14","author":"N Sturm","year":"2022","unstructured":"Sturm, N., Schuhbaur, J. S., H\u00fcttner, F., Perkhofer, L. & Ettrich, T. J. Gallbladder cancer: current multimodality treatment concepts and future directions. Cancers 14(22), 5580 (2022).","journal-title":"Cancers"},{"issue":"4","key":"36231_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4143\/crt.2017.279","volume":"50","author":"Y Wi","year":"2018","unstructured":"Wi, Y., Woo, H., Won, Y-J., Jang, J-Y. & Shin, A. Trends in gallbladder cancer incidence and survival in Korea. Cancer Res. Treat. 50(4), 1444\u20131451 (2018).","journal-title":"Cancer Res. Treat."},{"key":"36231_CR3","doi-asserted-by":"publisher","unstructured":"Guo, H. et al. Global burden of gallbladder cancer in 2022 and predictions to 2042. Digest. Liver Dis. 57(6), 1294\u20131300. https:\/\/doi.org\/10.1016\/j.dld.2025.02.007 (2025).","DOI":"10.1016\/j.dld.2025.02.007"},{"key":"36231_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12939-021-01596-y","volume":"20","author":"J Khanali","year":"2021","unstructured":"Khanali, J. et al. Global, regional, and national quality of care of gallbladder and biliary tract cancer: a systematic analysis for the global burden of disease study 1990\u20132017. Int. J. Equity Health. 20, 1\u20133 (2021).","journal-title":"Int. J. Equity Health"},{"key":"36231_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/cco.2019.08.03","volume":"8","author":"U Dutta","year":"2019","unstructured":"Dutta, U., Bush, N., Kalsi, D., Popli, P. & Kapoor, V. K. Epidemiology of gallbladder cancer in India. Chin. Clin. Oncol. 8, 33. https:\/\/doi.org\/10.21037\/cco.2019.08.03 (2019).","journal-title":"Chin. Clin. Oncol."},{"key":"36231_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amsu.2019.06.001","volume":"44","author":"I Sulieman","year":"2019","unstructured":"Sulieman, I., Elmoghazy, W., El Ansari, W., Elaffandi, A. & Khalaf, H. Gallbladder cancer: 7-year experience from Qatar. Ann. Med. Surg. 44, 33\u201338 (2019).","journal-title":"Ann. Med. Surg."},{"key":"36231_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4103\/jcrt.JCRT_896_19","volume":"18","author":"D Kumar","year":"2022","unstructured":"Kumar, D. et al. A comparative study of gemcitabine and cisplatin versus oral capecitabine alone in metastatic gallbladder cancer. J. Can. Res. Ther. 18, 939\u2013945 (2022).","journal-title":"J. Can. Res. Ther."},{"key":"36231_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1440-1746.2005.03576.x","volume":"20","author":"Y Batra","year":"2005","unstructured":"Batra, Y. et al. Gallbladder cancer in india: A dismal picture. J. Gastroenterol. Hepatol. 20, 309\u2013314 (2005).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"36231_CR9","first-page":"2","volume":"7","author":"MA Barbhuiya","year":"2009","unstructured":"Barbhuiya, M. A., Singh, T. D., Gupta, S., Shrivastav, B. R. & Tiwari, P. K. Incidence of gallbladder cancer in rural and semi urban population of north central India: A first insight. Internet J. Epidemiol. 7, 2\u201325 (2009).","journal-title":"Internet J. Epidemiol."},{"issue":"5","key":"36231_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/cancers14051249","volume":"14","author":"ZI Hu","year":"2022","unstructured":"Hu, Z. I. & Lim, K. H. Evolving paradigms in the systemic treatment of advanced gallbladder cancer: updates in year 2022. Cancers 14(5), 1249 (2022).","journal-title":"Cancers"},{"issue":"5","key":"36231_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jhbp.439","volume":"24","author":"A Ramaswamy","year":"2017","unstructured":"Ramaswamy, A. et al. Gemcitabine-cisplatin versus gemcitabine\u2010oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. J. Hepatobiliary Pancreat. Sci. 24(5), 262\u2013267 (2017).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"8","key":"36231_CR12","first-page":"EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evi. 1(8), EVIDoa2200015 (2022).","journal-title":"NEJM Evi"},{"issue":"10391","key":"36231_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391), 1853\u20131865 (2023).","journal-title":"Lancet"},{"issue":"6","key":"36231_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff, R. T. et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. JAMA Oncol. 5(6), 824\u2013830 (2019).","journal-title":"JAMA Oncol."},{"issue":"5","key":"36231_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO-24-01383","volume":"43","author":"RT Shroff","year":"2025","unstructured":"Shroff, R. T. et al. SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J. Clin. Oncol. 43(5), 536\u2013544 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"36231_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"36231_CR17","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (Accessed 14 Jun 2025). https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf  (National Cancer Institute, 2009)."},{"key":"36231_CR18","unstructured":"Kirkpatrick, L. & Feeney, B. A simple guide to IBM SPSS: for version 24.0. (Nelson Education, 2012)."},{"key":"36231_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9, T. et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann. Oncol. 15, 1339\u20131343 (2004).","journal-title":"Ann. Oncol."},{"issue":"8","key":"36231_CR20","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","volume":"90","author":"DC Doval","year":"2004","unstructured":"Doval, D. C. et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br. J. Cancer. 90(8), 1516\u20131520 (2004).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"36231_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00280-007-0444-5","volume":"61","author":"J Lee","year":"2008","unstructured":"Lee, J. et al. Korean Cancer Study Group. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother. Pharmacol. 61(1), 47\u201352 (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"36231_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00280-010-1351-8","volume":"67","author":"D Goldstein","year":"2011","unstructured":"Goldstein, D. et al. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother. Pharmacol. 67(3), 519\u2013525 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"14","key":"36231_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36231-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:37:12Z","timestamp":1783060632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36231-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36231"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36231-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20372"}}